Showing 991-1000 of 10032 results for "".
Psoriasis Update 2025: Dr. Gelfand
https://practicaldermatology.com/programs/practical-dermatology/psoriasis-update-2025-dr-gelfand/32672/Joel Gelfand, MD, MSCE, discusses highlights from the "Psoriasis Update 2025" panel at Maui Derm 2025, including the potential for combining TNF inhibitors with IL-23 inhibitors; home phototherapy; and the possibility of GLP-1 agonists lowering the severity of psoriatic disease.Get Ready for JAK Inhibitors
https://practicaldermatology.com/topics/psoriasis/get-ready-for-jak-inhibitors/19928/JAK inhibitors are going to change the way we think about refractory disease, says Brett King, MD. He addresses the significant increase in study of these agents and the many potential uses for refractory diseases like alopecia, atopic dermatitis, vitiligo, psoriasis, and more.Developing PsA: Risk Factors for Psoriasis Patients
https://practicaldermatology.com/topics/psoriasis/developing-psa-risk-factors-for-psoriasis-patients/19651/Can patients with psoriasis lessen their chance of developing psoriatic arthritis? Ronald Prussick, MD discusses the known risk factors and the importance of weight and a low BMI for these patients. He also talks about non-alcoholic fatty liver syndrome in this patient population.Topical Toxins: Now and Later
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/topical-toxins-now-and-later/18768/Topical neurotoxins are in late-stage development, with the potential to offer "softer" results and reduction of fine wrinkles. But they may not be approved for another few years. In the meantime, micro channel delivery of toxins, such as with AquaGold, is an option. Joel Schlessinger, MD, founder oReflecting on 2016: Big Stories in Acne, Psoriasis and AD
https://practicaldermatology.com/topics/psoriasis/reflecting-on-2016-big-stories-in-acne-psoriasis-and-ad/20845/Columnists take stock of advancements over the last 12 months, with a focus on clinical implications.A Mainstay in Treating Acne: The Role of Benzoyl Peroxide
https://practicaldermatology.com/topics/acne-rosacea/a-mainstay-in-treating-acne-the-role-of-benzoyl-peroxide/23307/Products like La Roche-Posay’s Effaclar Duo are effective in the management of acne.Device-Based Approaches to Acne and Rosacea
https://practicaldermatology.com/topics/psoriasis/device-based-approaches-to-acne-and-rosacea/20485/Leading dermatologists share pearls on device-based acne and rosacea treatments.Acne and Rosacea Awareness: Clinician Perspectives
https://practicaldermatology.com/topics/acne-rosacea/acne-and-rosacea-awareness-clinician-perspectives/23927/Key ways to improve treatment outcomes for patients with rosacea and acne.The Next Big Thing: Aesthetics in 2016
https://practicaldermatology.com/topics/practice-management/the-next-big-thing-aesthetics-in-2016/21035/Industry leaders share their predictions for what we will be talking about this year in aesthetic dermatology.Tri-State Analysis of the Distribution of Southeastern Dermatologists and Dermatology Residency Graduates Among Rural and Urban Areas
https://practicaldermatology.com/issues/november-2024/tri-state-analysis-distribution-southeastern-dermatologists-and-dermatology-residency-graduates-among-rural-and-urban-areas/29799/The nation faces a shortage of dermatologists, and this issue is most prevalent in rural areas. The objective of this study is to analyze the distribution of dermatologists and graduates of dermatology residency programs across the southeastern region and the factors that influence this distribution